Compare Raymond James Financial, Inc. (RJF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Raymond James Financial, Inc. trades at $175.81 (market cap $33.96B), while State Street SPDR S&P Biotech ETF trades at $160. The key difference: Raymond James Financial, Inc. pays a 1.22% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| RJF | XBI | |
|---|---|---|
Market Cap | $33.96B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $181.18 | $169.55 |
52-Week Low | $140.89 | $93.43 |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $176.55, down 0.98% on the day, with a bullish earnings trend after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Recent Q3 2026 results showed record revenues of $3.93 billion, up 16% year-over-year, driven by wealth management growth and investment banking recovery.
RJF presents a compelling investment case with strong fundamentals and analyst support, though technical indicators suggest near-term caution. The consensus price target of $184.11 implies 4.3% upside potential, with no sell ratings among 25 analysts. Key risks include rising expenses and capital markets volatility, while the company's advisor recruitment momentum and dividend payments provide stability.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
